Newton, Massachusetts – June 2015.

NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces two additions to the Medical Advisory Board (MAB) to advise on the company’s NH02D program for the treatment of premature ejaculation (PE).  The MAB assists NeuroHealing in the scientific and clinical development of its novel mechanism of action PE drug NH02D.

The new members of the company’s MAB are:

Dr. Michael A. Werner is a board-certified urologist who received his specialized fellowship training in male infertility and surgery and male sexual dysfunction at Boston University Medical Center. He lectures and writes extensively on these topics in medical journals and books.  Dr. Werner completed his Urology residency at Mount Sinai Medical Center in Manhattan and received his medical school training at the University of California at San Francisco. He holds an undergraduate degree in Biology from Harvard College.  Dr. Werner is the Founder and Director of a leading New York treatment facility for male infertility and male sexual dysfunction.

Dr. Ravi Kacker is a Urologist and Clinical Instructor at Harvard Medical School and Andrology and Infertility expert at Men’s Health Boston. Dr. Kacker is a urologic surgeon, clinical study investigator and an active scientific researcher in the areas of testosterone and cardiometabolic health, pelvic and testicular pain, and chronic prostatitis.  Dr. Kacker studied biomaterials and drug delivery prior to his career in medicine.  He has published over 25 publications which have influenced clinical practice and FDA opinion.  Dr. Kacker is the Founder and CEO of MHB Labs, a start-up developing next generation of male hormonal therapies.

About the author